This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Orplatna
Description: Satraplatin is a member of the platinum family of compounds. Over the past two decades, platinum-based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Unlike the platinum drugs currently on the market, all of which require intravenous administration, Satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home.
Deal Structure: Johnson Matthey PLC developed satraplatin and Spectrum in-licensed satraplatin in 2001. On September 30, 2002, Spectrum entered into a Co-Development and License agreement with GPC Biotech for the development and commercialization of satraplatin. Under this agreement, GPC Biotech has agreed to fully fund development and commercialization expenses for satraplatin. Spectrum may receive up to $22 million in license fees and milestone payments.
On December 20, 2005, GPC Biotech AG and Pharmion Corporation announced that the companies entered into a co-development and license agreement for satraplatin.
Under the terms of the agreement, Pharmion gains exclusive commercialization rights for Europe, Turkey, the Middle East, Australia and New Zealand, while GPC Biotech retains rights to the North American market and all other territories. Pharmion is to provide an upfront payment of $37.1 million to GPC Biotech, including an $18 million reimbursement for past satraplatin clinical...See full deal structure in Biomedtracker
Partners: Johnson Matthey Plc Spectrum Pharmaceuticals, Inc. Yakult Honsha Co. Ltd.
Pink Sheet Satraplatin gets ODAC review
Pink Sheet FDA Grants Satraplatin Priority Review
Additional information available to subscribers only: